Lovenox ANDA filings
Executive Summary
Two generic firms - Amphastar and Teva - have filed Paragraph IV certifications against Lovenox (enoxaparin), Aventis announces. The certifications challenge the product's 5,389,618 patent, which expires in February 2012, but not its 4,692,435 patent, which expires in December 2004. Aventis is seeking a re-issuance of the '618 patent as part of its patent defense of the low-molecular weight heparin (1"The Pink Sheet" May 5, 2003, p. 10). ANDA filings for the product attracted attention in early April when FDA posted, and then removed, Lovenox from the list of products which have Paragraph IV certifications. Amphastar said that its ANDA was approved for filing April 21...
You may also be interested in...
Aventis Lovenox Generics Defense Includes Re-Issuance Of Patent
Aventis plans to file an application for the re-issuance of a patent relating to its low molecular weight heparin agent Lovenox, the company told analysts April 30
Second EU MDR Notified Body Designated In France
Four years after the designation of the first notified body in France under the Medical Device Regulation, AFNOR Certification has been named too.
Takeda, Astellas Found New JV To Support Japanese Bioventures
Major Japanese companies Takeda, Astellas and SMBC are joining hands to establish a new joint venture with $3.9m capital and based in Japan’s largest biocluster Shonan iPark to help incubate local biopharma start-ups.